EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action
Marinomed Biotech AG sets price range for potential 10% capital increase
and potential second capital increase, in each case excluding statutory
subscription rights
15-Sep-2024 / 17:49 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the
Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
Group AG.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Korneuburg, Austria, 15. September 2024 – Marinomed Biotech AG (the
“Company”) announces that today the Management Board decided to set a
price range of EUR 4.90 to a maximum of EUR 5.20 per new share for a
potential capital increase of up to 154,053 new shares to be issued under
the Authorized Capital 2024 and subject to the direct exclusion of the
statutory subscription rights of existing shareholders (the “First Capital
Increase”; for an evaluation of this capital measure, see the ad hoc
announcement dated September 02, 2024). Within this price range, the
Management Board may decide to carry out the First Capital Increase (in
which members of the Management Board and Supervisory Board would also be
expected to participate), depending on the final negotiations with
selected investors and with the approval by the Supervisory Board, and set
the final offer price. The volume of the First Capital Increase
corresponds to up to 10% of the Company's existing share capital. Proceeds
from the capital increase are to be used in particular to finance the
running costs of the restructuring proceedings, to finance part of the
proposed restructuring plan and to cover the costs of continuing business
operations.
Furthermore, the Company is negotiating with an additional investor a
potential second capital increase of up to 154,053 additional shares to be
issued under the Authorized Capital 2024, which would be issued pursuant
to the authorization to exclude the statutory subscription rights of
existing shareholders in Section 5 paragraph 6 of the Company's articles
of association (the “Second Capital Increase”). The Management Board
resolved to set the same price range per new share for the potential
Second Capital Increase, whereby the Management Board – with the consent
of the Supervisory Board and upon satisfaction of the other necessary
conditions – intends to set the same offer price for the Second Capital
Increase as for the First Capital Increase.
The actual implementation of the respective capital increase is subject to
the outcome of the negotiations of details with the respective investors
and the conclusion of the respective transaction documents. At present, no
subscription agreements have been concluded and there are no binding
subscription declarations from investors for either of the two capital
increases. In addition to the further resolutions of the Management Board
and the approvals by the Supervisory Board required in each case, a report
on the planned exclusion of statutory subscription rights for the Second
Capital Increase must also be published at least two weeks before the
required Supervisory Board resolution. Furthermore, the restructuring
administrator must give her consent due to the ongoing restructuring
proceedings. This consent has not been obtained so far for either of the
two capital increases.
+++ End of ad-hoc announcement +++
End of Inside Information
══════════════════════════════════════════════════════════════════════════
15-Sep-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 1988245
End of Announcement EQS News Service
1988245 15-Sep-2024 CET/CEST
